The Peptide Authority

Research Hub

Sometimes called the “Wolverine Stack” — an informal online term, not a scientific or clinical name

BPC-157 and TB-500: Research on Tendon, Muscle & Tissue Recovery

BPC-157 and TB-500 are frequently discussed together in connection with tendon recovery, muscle recovery and soft-tissue repair — a combination sometimes referred to online as the “Wolverine Stack.”

Published human research on BPC-157 includes musculoskeletal pain studies and early human safety research. Current peer-reviewed reviews continue to examine BPC-157 in tissue repair, pain management and regenerative medicine.

TB-500 has its own published research record. This page brings together the most relevant evidence while keeping the individual evidence streams clearly identified.

This page summarizes published research only. It does not provide medical advice, prescribing guidance, dosing recommendations, or treatment recommendations.

Recovery Research at a Glance

A summary of the published evidence streams most relevant to tendon, muscle and tissue recovery.

Human Study

BPC-157 Human Musculoskeletal Research

A published human study evaluated intra-articular BPC-157 in patients with multiple types of knee pain, providing direct human musculoskeletal evidence.

Human Pilot Study

BPC-157 Human Safety Research

A 2025 pilot study evaluated intravenous BPC-157 in two adults and reported short-term human safety and tolerability findings.

Current Peer-Reviewed Research

BPC-157 Recovery Research

Recent peer-reviewed research reviews BPC-157 in tissue repair, pain management, regenerative medicine, muscle, tendon and ligament research.

Combination Research

BPC-157 + TB-500

BPC-157 and TB-500 are widely discussed together for tendon, muscle and soft-tissue recovery. Research involving the individual compounds continues to develop.

BPC-157 Evidence

Human BPC-157 Musculoskeletal Research

Human Retrospective Study·Alternative Therapies in Health and Medicine·2021

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Lee E, Padgett B·PMID 34324435

What Was Studied

A retrospective study evaluated intra-articular BPC-157 in patients with multiple types of knee pain.

Of the 16 patients successfully contacted for follow-up, 12 received BPC-157 alone. 4 received BPC-157 together with thymosin beta-4 (TB4).

Note: The paper describes the four-patient subgroup as BPC-157 + thymosin beta-4 (TB4). The paper does not identify that treatment as BPC-157 + TB-500.

Reported Human Results

BPC-157 alone

11 of 12

reported significant improvement in knee pain

BPC-157 + TB4

3 of 4

reported significant improvement

Why This Study Matters

This study provides published human musculoskeletal experience with BPC-157 in patients being treated for knee pain.

Research Context

The study was small and retrospective. Larger controlled studies are needed to determine how these findings translate across specific orthopedic injuries and recovery outcomes.

BPC-157 Evidence

Current BPC-157 Tissue-Repair Research

Peer-Reviewed Review·International Journal of Molecular Sciences·2026

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

Yuan C et al.·PMID 4189873310.3390/ijms27062876

Research Focus

This 2026 review examines BPC-157 across tissue repair, pain management and regenerative medicine.

The research areas reviewed include:

  • muscle healing
  • tendon healing
  • ligament healing
  • bone repair
  • collagen synthesis
  • fibroblast activity
  • vascular repair
  • inflammatory signaling
  • pain modulation

Why It Matters

This research helps explain why BPC-157 continues to receive attention in tendon, muscle and musculoskeletal recovery research while human clinical investigation continues to develop.

BPC-157 Evidence

BPC-157: Current Translational Research

Peer-Reviewed Review·Pharmaceutics·2026

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers

PMID 4219831710.3390/pharmaceutics18050625

This 2026 review examines BPC-157 as an investigational peptide therapeutic, including formulation, pharmacology and the clinical-development questions surrounding future human research.

Research Significance

The publication reflects the continuing movement of BPC-157 research toward formulation, human translation and future clinical development.

BPC-157 Evidence

Human BPC-157 Safety Research

Human Pilot Study·Alternative Therapies in Health and Medicine·2025

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee E, Burgess K·PMID 40131143

What Was Studied

Two adults participated in an IRB-approved pilot study evaluating intravenous BPC-157. Participants received 10 mg during the first study exposure and 20 mg during the second study exposure while vital signs and laboratory markers were monitored.

Reported Findings

The investigators reported no measurable adverse changes in the monitored cardiac, liver, kidney, thyroid or glucose markers during the short study period. Neither participant reported side effects.

Why It Matters

This study contributes direct human exposure and short-term safety information to the published BPC-157 research record. It was designed as a safety study rather than a tendon or muscle recovery trial.

These amounts describe what was administered in the published study. They are not recommendations, dosing protocols, or injection instructions.

TB-500 Evidence

What Is TB-500?

Analytical Characterization·Drug Testing and Analysis·2012

Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

Esposito S et al.Ghent University Doping Control Laboratory·PMID 2296202710.1002/dta.1402

Researchers analyzing material identified as TB-500 detected the N-terminal acetylated 17–23 fragment of human thymosin beta-4:

Ac-LKKTETQ

N-terminal acetylated 17–23 fragment of thymosin beta-4

Why It Matters

This peer-reviewed analysis provides a direct published identity reference for TB-500. It helps distinguish TB-500-specific literature from research involving other thymosin-derived compounds.

Research Context

Why Are BPC-157 and TB-500 Discussed Together?

BPC-157 and TB-500 have developed overlapping interest around tendon recovery, muscle recovery, soft-tissue repair and musculoskeletal health.

The compounds come from different research pathways.

BPC-157 now has published human musculoskeletal research, human safety research and current peer-reviewed reviews examining tissue repair and regenerative medicine.

TB-500 has its own peer-reviewed analytical research record.

That overlap in recovery-focused research interest helps explain why BPC-157 + TB-500 — sometimes called the “Wolverine Stack” online — has become a prominent topic among people researching muscle, tendon and tissue recovery.

The term “Wolverine Stack” is informal online terminology and is not a standardized scientific or clinical name.

Research Summary

What the Current Research Shows

Research surrounding BPC-157 and TB-500 continues to develop across several areas relevant to recovery.

BPC-157 now has published human musculoskeletal research. A 2021 knee study reported improvement among most of the patients followed after receiving BPC-157 alone or BPC-157 with TB4.

BPC-157 also has direct human safety research, including a 2025 intravenous pilot study that adds early human exposure and tolerability data.

Current peer-reviewed reviews continue to examine BPC-157 in tissue repair, pain management, regenerative medicine and future clinical development.

TB-500 has a published analytical research record that helps establish its scientific identity and provides a foundation for interpreting TB-500-specific research accurately.

BPC-157 + TB-500 remains a developing recovery-research topic with particularly strong public interest around tendon, muscle and soft-tissue recovery.

As additional human studies and peer-reviewed publications become available, The Peptide Authority can continue expanding this research index.

Research Status

Current Evidence Status

BPC-157 Human Research

Published

Human studies exist in the published literature including a retrospective musculoskeletal study and a safety pilot.

BPC-157 Musculoskeletal Research

Published — Early Stage

A 2021 retrospective knee-pain study provides initial published human musculoskeletal evidence. Larger controlled studies are needed.

BPC-157 Human Safety Research

Published — Pilot Data

A 2025 intravenous pilot study in two adults adds short-term human safety and tolerability data.

BPC-157 Tissue-Repair Research

Active Peer-Reviewed Literature

Current peer-reviewed reviews examine BPC-157 across tissue repair, pain management and regenerative medicine.

TB-500 Identity Research

Published

Peer-reviewed analytical characterization of TB-500 is available in the published literature.

BPC-157 + TB-500 Combination Research

Developing Evidence Base

Individual compound research continues to develop. A controlled human trial of the exact BPC-157 + TB-500 combination has not been verified in the peer-reviewed literature.

Published Sources

Published Sources

All sources used on this page. Links go directly to PubMed or DOI.

1

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Lee E, Padgett B · 2021

PMID 34324435
2

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee E, Burgess K · 2025

PMID 40131143
3

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

Yuan C et al. · 2026

PMID 4189873310.3390/ijms27062876
4

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers

2026

PMID 4219831710.3390/pharmaceutics18050625
5

Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

Esposito S et al. · 2012

PMID 2296202710.1002/dta.1402

Research Library indexing note

The evidence records on this page are curated editorially and are not part of The Peptide Authority’s global indexed study database. All source links are direct references to PubMed or DOI. The Research Library indexes only PubMed-registered publications with assigned PMIDs or DOIs and institutional authorship.

Browse the full Research Library

Evidence Briefing

The Peptide Evidence Brief

Twice each month, receive the most important newly indexed studies, clinical trial updates, evidence summaries, and research developments, selected exclusively from trusted peer-reviewed journals.

Concise summaries with direct links to original publications. Quality over quantity. No promotional content.

Peer-reviewed sources onlyPublished twice monthlyNo promotional content

No spam. Unsubscribe at any time. We never share your data.